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Introduction 
The first data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin 
type 9 (PCSK9) inhibitors have now been reported.1,2 The FOURIER trial (with evolocumab, a 
fully human monoclonal PCSK9 antibody) in 27,564 patients with atherosclerotic cardiovascular 
disease (ASCVD) was completed.1 The SPIRE-1 and 2 trials were, however, stopped early 
following termination of bococizumab due to effects specific to this humanized antibody 
(Box 1).2,3 In FOURIER, lowering of low-density lipoprotein cholesterol (LDL-C) levels by 59% 
(from 2.4 mmol/L to 0.78 mmol/L) significantly reduced the risk of major cardiovascular events 
(absolute event rates 9.8% versus 11.3% on placebo over 2.2 years, relative risk reduction of 
15%, p<0.001). The clinical benefit of PCSK9 inhibitor treatment was largely consistent across all 
major patient subgroups, including age, sex, and type of clinical presentation of ASCVD 
(coronary artery disease with history of myocardial infarction [MI], ischaemic stroke and 
symptomatic peripheral arterial disease PAD]), and accrued over time.1 The observed benefit in 
FOURIER was shown to fall below the Cholesterol Treatment Trialists’ Collaboration (CTTC) 
regression line for cardiovascular benefit per mmol/L reduction in LDL-C, based on average 
response over 5 years on statin therapy. When compared for the same duration of treatment, 
however, the results were superimposable with that observed with statin therapy (Figure 1).4,5 
Evidence from studies involving variants in the genes encoding PCSK9 and HMGCoA reductase 
provides further support for the concept that a similar risk reduction per unit LDL-C reduction is 
to be expected.6 
 
Insights from these trials reinforce that the key determinants of clinical benefit are the absolute 
cardiovascular risk, the absolute magnitude of LDL-C reduction and the absolute LDL-C burden.  
In all trials, patients were at very high risk as defined by the 6th Joint Task Force guidelines,7 
with a history of clinical ASCVD (either MI, stroke or symptomatic PAD) and additional 
cardiovascular risk factors, including clinically diagnosed familial hypercholesterolaemia (FH) 
(SPIRE trials).1,2 Patients had a substantial residual LDL-C burden despite maximally tolerated 
lipid lowering therapy (most were receiving high to moderate intensity statin). In SPIRE-2, 
patients had a higher residual LDL-C burden (mean LDL-C at baseline 3.4 mmol/L or 133 mg/dl 
versus 2.4 mmol/l or ~90 mg/dl in FOURIER and SPIRE-1).1,2 Thus, despite progressive 
attenuation of LDL-C lowering with bococizumab due to the formation of neutralizing 
antibodies,3 there was significant clinical benefit in SPIRE-2 within 12 months (absolute event 
rates for major cardiovascular events 3.32% versus 4.19% on placebo, relative risk reduction of 
21%, p=0.02). In contrast, SPIRE-1 with lower residual LDL-C burden and shorter duration of 
treatment (7 months), did not show significant differences in cardiovascular events.2  
 
Two key issues have been raised regarding FOURIER. The first issue relates to the rather short 
duration of the trial.  It is important to emphasize that the trial was event- and not time-driven. 
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Allowing for a possible lag in treatment benefit, as seen in the statin trials, FOURIER planned for 
a median duration of ~43 months to allow for accrual of 1,630 key secondary end points (a 
composite of cardiovascular death, MI or stroke), which would provide 90% power to detect a 
relative reduction of ≥15% for this endpoint.8 In reality, the observed event rate was higher and 
therefore the trial was completed after a median of 2.2 years after 1,829 key secondary 
endpoints had occurred.1  
The second issue relates to the lack of significant benefit on cardiovascular and all-cause 
mortality. Inspection of the FOURIER data shows that the predominant effect of PCSK9 
inhibition was prevention of non-fatal cardiovascular events, including coronary 
revascularization; cardiovascular mortality was mainly attributed to reasons other than MI or 
stroke.1 These findings are consistent with trials evaluating high- versus low-dose statin 
therapy, none of which showed reduction in cardiovascular death. Added to this, a meta-
analysis of four high- versus low-dose statin trials indicated a reduction predominantly in non-
fatal cardiovascular events.9  Moreover, while reduced mortality was observed in earlier statin 
trials (e.g. 4S trial)10, this was only seen after prolonged treatment and not after 2.2 years 
against a background of current evidence-based therapy as in FOURIER. It will therefore be of 
great interest to see whether longer follow-up of patients treated with a PCSK9 inhibitor 
provides evidence of reduced mortality. 
Together with definitive evidence that LDL is causal for ASCVD,11 the results of the FOURIER and 
SPIRE trials constitute a key step forward in addressing unanswered questions about PCSK9 
inhibition in the previous Task Force document.12 It should, however, be noted that while the 
FOURIER and SPIRE-1 and SPIRE-2 protocols permitted enrolment of  patients with mild to 
moderate chronic kidney disease, there is currently no available data on which to base 
recommendations for the use of PCSK9 inhibitors.  Furthermore, while there is reassurance 
regarding the safety of very low LDL-C levels that can be attained on PCSK9 inhibitor 
therapy,13,14 this Task Force recognizes that these data are limited in large part to the 
observation period of the clinical trials. Given the current high treatment cost, an acceptable 
cost versus benefit ratio will only be achieved in very high risk patients with substantial residual 
LDL-C burden, where the relative risk reduction with PCSK9 inhibition can be translated into a 
significant absolute risk reduction over the trajectory of ASCVD. The remit for this ESC/EAS Task 
Force, therefore, is to consider the impact of this new evidence on recommendations for 
practical guidance for the use of PSK9 inhibitors in clinical practice.  
 
Defining patients considered for treatment with a PCSK9 inhibitor 
On the basis of available evidence, this Task Force recommends that a PCSK9 inhibitor should 
be considered in the following patient groups. 
• Patients with ASCVD, by definition at very high risk,7 who have a substantial residual 
LDL-C burden despite maximally tolerated statin + ezetimibe therapy, and thus are 
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considered at particularly high risk of an adverse prognosis. In addition, patients with 
ASCVD who do not tolerate appropriate doses of at least three statins (± ezetimibe) and 
thus have a high residual LDL-C burden, should also be considered.  
• In FH patients without clinically diagnosed ASCVD, at high or very high cardiovascular 
risk, and with substantial residual LDL-C burden despite maximally tolerated statin + 
ezetimibe therapy. 
 
Patients with ASCVD 
As exemplified by FOURIER, patients with documented clinical ASCVD are at very high 
cardiovascular risk, with an annual absolute risk of a major cardiovascular event >3%.7,15 The 
recommended first approach to management of elevated LDL-C levels in these patients is 
intense statin therapy.16  Clinicians should allow sufficient time to achieve the maximum 
tolerated regimen of statin therapy;17 FOURIER illustrates this in practice, with 69.3% of 
patients on high intensity statin and only 30.4% on moderate intensity statin.1  While add-on 
ezetimibe provides a further 19-23% reduction in LDL-C levels,18,19 this may be insufficient in 
very high risk patients who typically require >50% reduction to attain the recommended LDL-C 
goal. 
 
In these very high risk patients with substantial residual LDL-C burden (>3.6 mmol/L or 140 
mg/dl) despite statin + ezetimibe therapy or inability to tolerate appropriate doses of at least 
three statins (± ezetimibe), clinicians should consider addition of a PCSK9 inhibitor. Lowering 
LDL-C levels by at least 50% with this therapy will result in >1% annual reduction in absolute 
cardiovascular risk.15 This Task Force recognizes that the presence of additional indices of risk 
severity, such as rapidly progressive ASCVD, in particular after an acute coronary syndrome, 
diabetes mellitus, or complex multivessel or polyvascular atherosclerotic disease, exacerbates 
absolute risk.7,20 Therefore, a lower LDL-C threshold is recommended for consideration of 
PCSK9 inhibition (>2.6 mmol/L or 100 mg/dl) in these patients (Figure 2). Where available in 
routine practice, imaging may help to identify patients with complex multivessel ASCVD who 
are at particularly high risk (Box 2). Simple non-invasive measures could be used, for example in 
a patient with MI detection of carotid disease using Doppler scanning, or PAD using Ankle 
brachial pressure index measurement could easily confirm or refute multivessel disease and the 
need for aggressive management. 
A PCSK9 inhibitor should be considered in ASCVD patients with substantial residual LDL-C 
burden despite maximally tolerated statin + ezetimibe therapy, or inability to tolerate 
appropriate doses of at least three statins (± ezetimibe), especially if there are additional 
indices of risk severity, i.e. FH, multivessel or polyvascular disease or with rapidly progressive 
ASCVD.  
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FH patients without clinically diagnosed ASCVD 
In routine clinical practice, FH is typically diagnosed using approaches such as the Dutch Lipid 
Clinic Network criteria, with or without genetic testing, as recommended in the previous Task 
Force statement.12 The elevated cardiovascular risk of undertreated heterozygous FH patients is 
well recognized.21-24 As shown by the SAFEHEART registry, this risk increases >8-fold in patients 
with an FH-causative mutation compared with unaffected relatives,22 and by 3-4 fold in patients 
with an FH-causative mutation and LDL-C levels >4.9 mmol/L (>190 mg/dl).25,26 Furthermore, 
despite long-term, high-intensity statin treatment to lower LDL-C levels, asymptomatic FH 
patients often have evidence of an increased plaque burden in multiple vascular territories.25,27 
As there are no clinical outcomes studies in FH patients, estimates of absolute cardiovascular 
risk are based on data from clinical trials and registries such as SAFEHEART.28,29 With maximally 
tolerated statin + ezetimibe therapy (the recommended treatment in FH)16,21, annual 
cardiovascular event rates are estimated at 1%, increasing with the presence of additional risk 
factors (such as marked hypertension, smoking, and lipoprotein(a) >50 mg/dl).28  
 
Treatment decisions are currently guided by the LDL-C level and the presence of additional 
indices of risk severity.12 Clinicians should make every effort to ensure achievement of the 
maximally tolerated statin dose regimen, in accordance with current guidance.17 Imaging may 
also have a role in guiding therapy, as evidence of increased plaque burden with ultrasound 
evaluation or computed tomographic angiography has been shown to be indicative of 
premature ASCVD and high risk for cardiovascular events.30 
 
Given their high absolute risk, FH patients with substantial residual LDL-C burden on maximally 
tolerated statin + ezetimibe therapy require at least 50% lowering of LDL-C levels to optimally 
impact cardiovascular risk. Taking account of recent evidence from SAFEHEART,28 this Task 
Force recommends that clinicians should consider a PCSK9 inhibitor in FH patients without 
clinically diagnosed ASCVD, including young FH patients, when LDL-C levels are >4.5 mmol/L 
(>180 mg/dl) despite maximally tolerated statin + ezetimibe therapy.  A lower LDL-C threshold 
(>4.0 mmol/L or >160 mg/dl) is recommended when patients have additional indices of risk 
severity (Figure 3). This approach can reduce the need for lipoprotein apheresis, a costly and 
invasive procedure which is rather inconvenient to patients and their carers.31  
 
As in the previous Task Force document, evolocumab is recommended as an additional 
therapeutic option to reduce LDL-C levels in patients with homozygous FH, with or without 
apheresis, except in those with confirmed negative/negative LDLR mutations.12,32 With the very 
high risk of these patients due to the cumulative burden of very high LDL-C levels, most are 
likely to have already experienced clinical events. 
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• A PCSK9 inhibitor may be considered in heterozygous FH patients clinically diagnosed 
ASCVD if there is substantial residual LDL-C burden despite maximally tolerated statin + 
ezetimibe therapy.  
• The LDL-C threshold for consideration of PCSK9 inhibition is lower if there are additional 
indices of risk severity (refer to fig 3). 
 
Monitoring LDL-C lowering response  
Response to initiation or dose adjustment of lipid lowering treatment (statin or add-on 
ezetimibe) can be assessed at 4-8 weeks.16 As a minimum, LDL-C levels should be monitored, 
but a comprehensive lipid profile may facilitate better management decisions. Failure to attain 
LDL-C goal may be due to a number of factors including pharmacogenetic effects associated 
with reduced responsiveness, an inability to tolerate adequate statin doses and lack of 
adherence.12,16 Consequently, if the patient is not at LDL-C goal on maximally tolerated statin 
therapy, adherence should be first checked and the clinician should reinforce the importance of 
treatment compliance as a determinant of improved cardiovascular outcome.33 If adherence is 
shown to be satisfactory, the clinician should consider add-on ezetimibe treatment. If after 4-8 
weeks the LDL-C lowering response is still inadequate and the patient is adherent with 
treatment, addition of a PCSK9 inhibitor should be considered (Figure 4).  
 
Following a single injection of alirocumab or evolocumab, complete PCSK9 inhibition occurs 
within 3-4 days with the nadir in LDL-C lowering response at 11-15 days.34,35 This response is 
similar for either regimens of alirocumab or evolocumab.36 Information documenting the inter-
individual variability in the LDL-C lowering response to PCSK9 inhibition is, however, limited.  
This is a pertinent issue, in the light of evidence from the SPIRE programme (see Box 1).3 In an 
analysis of trial data from more than 4,700 patients treated with alirocumab for up to 78 weeks, 
1.2% of patients developed persistent antidrug antibodies with the 150 mg 2-weekly regimen 
and 1.8% with the 75/150 mg 2-weekly regimen.37 Antidrug antibodies were developed by 0.3% 
of patients allocated to evolocumab in FOURIER, and 0.3% (4 patients) in the open-label OSLER-
1 extension study (2 patients each who were initially allocated to standard of care or 
evolocumab, and then received the alternative treatment during long-term follow-up).1,14 In the 
absence of extensive documentation of variability in the inter-individual response, this Task 
Force recommends that clinicians should monitor the LDL-C lowering response to alirocumab or 
evolocumab as indicated below and in Figure 4. 
 
• Monitor the LDL-C lowering response to statin ± ezetimibe at 4-8 weeks and check 
adherence before considering a PCSK9 inhibitor.  
• Assess the LDL-C lowering response to the PCSK9 inhibitor at 10-14 days after first 
injection of either the monthly or 2-weekly regimen.  
Future perspectives and gaps in knowledge  
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Despite this new evidence from FOURIER and, to a lesser degree SPIRE, gaps remain in our 
knowledge regarding the use of PCSK9 inhibition in clinical practice (Box 3). ODYSSEY Outcomes 
will provide additional information in patients treated with a PCSK9 inhibitor within 1-12 
months (median 2.6 months, interim data) of an acute coronary syndrome.38,39 
As with all novel treatments, long-term safety remains to be established. To date there are 
exposure data for up to 4 years’ treatment with a PCSK9 inhibitor, including patients with 
heterozygous FH, predominantly involving a background of concomitant statin therapy.14,40,41 
Potential injection site reactions occurred in <5% of patients, and were mainly of very mild 
intensity with no evidence of a cumulative effect. Compared with standard of care (statin 
±ezetimibe), the incidences of muscle-related symptoms, especially important in PAD, (8% 
versus 9%), and new-onset diabetes (4.1% versus 4.3%) on a PCSK9 inhibitor appear similar.14 
There is no evidence for an increase in the risk of haemorrhagic stroke, although the point 
estimate reported in FOURIER was similar to that observed in the CTT meta-analysis.1,4  
The safety of very low LDL-C levels merits special consideration, given that one in four patients 
treated with evolocumab in FOURIER attained LDL-C levels less than 0.52 mmol/L or 20 mg/dl.1 
Evidence to date, including patients with rare genetic traits associated with very low LDL-C 
levels, suggests no detrimental impact on steroid hormone production, enterohepatic 
circulation of bile acids, and neuronal cell function.42 Additionally, data from the ODYSSEY 
programme, FOURIER and 6-year follow-up from IMPROVE-IT showed no increase in adverse 
events including severe muscle symptoms, liver enzyme elevation, cognitive adverse events, or 
haemorrhagic stroke with very low LDL-C levels.1,13, 41 The EBBINGHAUS trial, a substudy of 
FOURIER in 1,204 patients (mean age 63 years), specifically evaluated effects on neurocognitive 
function using a robust well-validated testing platform (Cambridge Neuropsychological Test 
Automated Battery [CANTAB] Assessment). This study showed no detriment, even in patients 
attaining LDL-C levels <0.65 mmol/l (<25 mg/dl).43 Long-term evaluation, especially in older 
patients (>75 years), is nonetheless warranted. 
In summary, this Task Force concludes that available evidence for the safety of PCSK9 
inhibition, and specifically for very low LDL C levels attained on treatment, is reassuring 
although further long-term surveillance is clearly indicated.   
 
Health economics 
The introduction of innovative therapeutic agents for the treatment of chronic disease states in 
large patient populations has important health economic implications. Patient groups at very 
high cardiovascular risk are likely to be a priority for treatment, although access is ultimately 
determined by the societal willingness-to-pay threshold based on quality-adjusted life-years 
gained.  
Detailed discussion of cost-effectiveness analyses of PCSK9 inhibition in the proposed priority 
groups is beyond the remit of this Task Force. While some have concluded that the cost of 
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treatment far exceeds the societal willingness to pay threshold,44 others have argued that 
about one-half of this cost would be saved by reduction in direct and indirect disease-related 
costs.45 It is important to bear in mind that absolute cardiovascular risk and absolute LDL-C 
levels are the key determinants of the number needed to treat (NNT) to prevent a 
cardiovascular event. In patients with ASCVD, and in FH patients without a prior event, who 
have a substantial LDL-C burden despite maximally tolerated statin ± ezetimibe therapy, or 
inability to tolerate statins, data from FOURIER suggest that adding a PCSK9 inhibitor to lower 
LDL-C levels by 50% might be expected to reduce the 5-year NNT to ≤30.1,15  Bearing in mind 
evidence from WOSCOPS of a legacy benefit from statin therapy,46 however, it would be 
presumptive to model the impact of adding a PCSK9 inhibitor on the NNT until longer-term 
follow-up data are available to assess the potential of these treatments to modify the trajectory 
of ASCVD.  
Recommendations for cost-effectiveness analysis relating to the judicious use of innovative 
treatments are also evolving.47 As highlighted by the European Atherosclerosis Society 
Consensus Panel Statement on LDL causality, the impact of therapy on lifetime cardiovascular 
risk needs to be considered, as in a recent analysis.11,48 Prioritizing the use of a PCSK9 inhibitor 
in the very high risk patient groups defined in this Task Force statement, with a substantial 
residual LDL-C burden despite maximally tolerated statin ± ezetimibe therapy or inability to 
tolerate statins, may therefore have the potential to be cost efficient.  Obviously, as these 
patients typically have multiple risk factors beyond elevated LDL-C, incorporation of simple 
preventive strategies, such as lifestyle interventions and blood pressure control, which have 
additive effects, is essential. 
Conclusions  
Having appraised the evidence from the first of the cardiovascular outcomes studies with PCSK9 
inhibitors, this Task Force concludes that addition of a PCSK9 inhibitor should be considered in 
patients with ASCVD, and in FH patients without a prior clinical event, who have a substantial 
residual LDL-C burden despite maximally tolerated statin ± ezetimibe therapy, or inability to 
tolerate appropriate doses of at least three statins (± ezetimibe). Low levels of LDL-C attained 
on a PCSK9 inhibitor appear to be safe within the observation period of clinical trials; indeed, 
these LDL-C levels are comparable with those in newborns, even with the elevated physiological 
demands of infancy.49 Prioritizing the use of this innovative therapy in these patient groups may 
also confer societal benefit when taking into account the impact of this treatment on lifetime 
cardiovascular risk.   
 
Funding and disclosure statements 
 
  
{ PAGE   \* MERGEFORMAT } of 21 
 
References 
1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang 
H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and 
Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl 
J Med 2017;376:1713-1722. 
2. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire 
J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller 
M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, 
White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome 
Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J 
Med 2017 20;376:1527-1539. 
3. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, 
Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE 
Investigators. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N 
Engl J Med 2017;376:1517-1526. 
4. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, 
Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker 
P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, 
Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 
2016;388:2532-2561. 
5. Ference BA, Cannon CP, Landmesser U, Lüscher TF, Catapano AL, Ray KK. Reduction of LDL-
cholesterol and cardiovascular events with PCSK9 inhibitors and statins – an analysis of 
FOURIER, SPIRE and the Cholesterol Treatment Trialists Collaboration. Eur Heart J 2017 (in 
press). 
6. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano 
RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and risk of 
cardiovascular dDisease and diabetes. N Engl J Med 2016 1;375:2144-2153. 
7. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, 
Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk 
J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, 
Verschuren WM. 2016 European Guidelines on cardiovascular disease prevention in clinical 
practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies 
on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 
societies and by invited experts) Developed with the special contribution of the European 
Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-
2381. 
{ PAGE   \* MERGEFORMAT } of 21 
 
8. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, 
Sever PS, Pedersen TR. Rationale and design of the Further cardiovascular OUtcomes Research 
with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016;173:94-101. 
9. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular 
outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 
2006;48:438-445.  
10..Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 
4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 
Lancet 1994;344:1383–1389. 
11. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, 
Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard 
BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, 
Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular 
disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement 
from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017 Apr 24. doi: 
10.1093/eurheartj/ehx144. [Epub ahead of print] 
12. Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, Lüscher TF, Sinning 
D, Tokgözoğlu L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL; European Society of 
Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Society of 
Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein 
convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high 
cardiovascular risk. Eur Heart J 2016 Oct 27. pii: ehw480. [Epub ahead of print] 
13. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, 
Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low 
levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial. 
JAMA Cardiol 2017 Mar 14. doi: 10.1001/jamacardio.2017.0083. [Epub ahead of print] 
14. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, 
Somaratne R, Raal FJ.  Long-term low-density lipoprotein cholesterol-lowering efficacy, 
persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 
years from the open-label OSLER-1 Extension Study. JAMA Cardiol 2017 Mar 14. doi: 
10.1001/jamacardio.2017.0747. [Epub ahead of print] 
15. Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add 
nonstatin therapy: a quantitative approach. J Am Coll Cardiol 2016;68:2412-2421. 
16. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings 
CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren 
WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the management of 
dyslipidaemias. Eur Heart J 2016;37:2999-3058. 
{ PAGE   \* MERGEFORMAT } of 21 
 
17. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, 
Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele 
RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, 
Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-
associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society 
Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 
2015;36:1012-1022. 
18. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. 
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of 
factors associated with treatment response. A pooled analysis of over 21,000 subjects from 27 
clinical trials. Atherosclerosis 2012; 223: 251-261. 
19. Catapano A, Toth PP, Tomassini JE, Tershakovec AM. The efficacy and safety of ezetimibe 
coadministered with statin therapy in various patients groups. Clin Lipidol 2013; 8: 13-41. 
20. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Röther J, Bhatt 
DL, Steg PG; REACH Registry Investigators. Influence of polyvascular disease on cardiovascular 
event rates. Insights from the REACH Registry. Vasc Med 2010;15:259-265. 
21. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, 
Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, 
Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven 
JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European 
Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed 
and undertreated in the general population: guidance for clinicians to prevent coronary heart 
disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 
2013;34:3478-3490a 
22. Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O, Galiana J, Figueras R, Diaz JL, 
Gomez-Enterría P, Mauri M, Piedecausa M, Irigoyen L, Aguado R, Mata P; Spanish Familial 
Hypercholesterolaemia Group. Cardiovascular disease in familial hypercholesterolaemia: 
influence of low-density lipoprotein receptor mutation type and classic risk factors. 
Atherosclerosis 2008;200:315-321. 
23. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in 
the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering 
medication. J Clin Endocrinol Metab 2012;97:3956–3964.  
24. deGoma EM, Ahmad ZS, O’Brien EC, Kindt I, Shrader P, Newman CB, Pokharel Y, Baum SJ, 
Hemphill LC, Hudgins LC, Ahmed CD, Gidding SS, Duffy D, Neal W, Wilemon K, Roe MT, Rader 
DJ, Ballantyne CM, Linton MF, Duell PB, Shapiro MD, Moriarty PM, Knowles JW. Treatment gaps 
in adults with heterozygous familial hypercholesterolemia in the United States: Data from the 
CASCADE-FH Registry. Circ Cardiovasc Genet 2016;9:240–249. 
{ PAGE   \* MERGEFORMAT } of 21 
 
25. Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes 
F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, 
Manjón L, Mauri M, Padró T, Miramontes JP, Mata P; SAFEHEART Investigators. Coronary heart 
disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from 
the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler 
Thromb Vasc Biol 2016;36:2004-2010. 
26. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan 
P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van 
Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, 
Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, 
Gabriel S, Kathiresan S.  Diagnostic yield and clinical utility of sequencing familial 
hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 
2016;67:2578-2589. 
27. Rubba P, Gentile M, Marotta G, Iannuzzi A, Sodano M, De Simone B, Jossa F, Iannuzzo G, 
Giacobbe C, Di Taranto MD, Fortunato G. Causative mutations and premature cardiovascular 
disease in patients with heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2017 
Jan 1:2047487317702040. [Epub ahead of print] 
28. Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, Saltijeral A, 
Fuentes-Jiménez FJ, de Andrés R, Zambón D, Piedecausa M, Cepeda JM, Mauri M, Galiana J, 
Brea Á, Sanchez Muñoz-Torrero JF, Padró T, Argueso R, Miramontes-González JP, Badimón L, 
Santos RD, Watts GF, Mata P; SAFEHEART investigators. Predicting cardiovascular events in 
familial hypercholesterolemia: the SAFEHEART Registry. Circulation. 2017 Mar 8. doi: 
10.1161/CIRCULATIONAHA.116.024541. [Epub ahead of print] 
29. Stein EA. PCSK9: the critical role of familial hypercholesterolemia from discovery to benefit 
for all. Cardiovasc Drugs Ther 2016;30:427–431. 
30. Sijbrands EJ, Nieman K, Budoff MJ; FH CTA Consortium. Cardiac computed tomography 
imaging in familial hypercholesterolaemia: implications for therapy and clinical trials. Curr Opin 
Lipidol 2015;26:586-592. 
31`. Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, 
Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, 
Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolaemia 
undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016;37:3588-3595. 
32. Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, 
Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA. Long-term 
treatment with evolocumab added to conventional drug therapy, with or without apheresis, in 
patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the 
open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017;5:280-290. 
{ PAGE   \* MERGEFORMAT } of 21 
 
33. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular 
disease and mortality outcomes: a systematic review. Br J Clin Pharmacol 2014;78:684-698. 
34. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, 
Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to 
PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118. 
35. Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne 
R, Wasserman SM, Blom D. Impact of target-mediated elimination on the dose and regimen of 
evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 
9 (PCSK9). J Clin Pharmacol 2017;57:616-626. 
36. Scherer N, Dings C, Böhm M, Laufs U, Lehr T. Alternative treatment regimens with the 
PCSK9 inhibitors alirocumab and evolocumab: A pharmacokinetic and pharmacodynamic 
modeling approach. J Clin Pharmacol 2017 Mar 6. doi: 10.1002/jcph.866. [Epub ahead of print] 
37. Roth EM, Goldberg AC, Catapano AL, Torri A, Yancopoulos GD, Stahl N, Brunet A, Lecorps G, 
Colhoun HM. Antidrug antibodies in patients treated with alirocumab. N Engl J Med 
2017;376:1589-1590. 
38. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, 
Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, 
Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a 
monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary 
syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014;168:682-689. 
39. Goodman SG, Schwartz GG, Bhatt DL, Bittner V, Diaz R, Hanotin C, Harrington RA, Jukema 
JW, Moryusef A, Pordy R, Roe MT, Sasiela WI, Szarek M, Tamby J-F, White H, Zeiher A, Steg PG, 
for the ODYSSEY OUTCOMES Investigators. Use of high-intensity statin therapy post-acute 
coronary syndrome in the ongoing ODYSSEY OUTCOMES trial of alirocumab, a proprotein 
convertase subtilisin/kexin type 9 monoclonal antibody, versus placebo: interim baseline data. 
Abstract 1203-307, Scientific Sessions of the American College of Cardiology, Washington D.C., 
17-19 March, 2017.  
40. Dufour R, Bergeron J, Gaudet D, Weiss R, Hovingh GK, Qing Z, Yang F, Andisik M, Torri A, 
Pordy R, Gipe DA. Open-label therapy with alirocumab in patients with heterozygous familial 
hypercholesterolemia: Results from three years of treatment. Int J Cardiol 2017;228:754-760. 
41. Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K, Kastelein 
JJ. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data 
From randomized trials. J Am Coll Cardiol 2017;69:471-482. 
42. Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von 
Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, 
{ PAGE   \* MERGEFORMAT } of 21 
 
Tikkanen MJ, Yvan-Charvet L. Can LDL cholesterol be too low? Possible risks of extremely low 
levels. J Intern Med. 2017 Mar 14. doi: 10.1111/joim.12614. [Epub ahead of print] 
43. EBBINGHAUS: No effect on neurocognition with evolucumab. ACC 2017 news story. 
http://www.acc.org/latest-in-cardiology/articles/2017/03/13/17/44/sat-8am-ebbinghaus-
cognitive-study-of-patients-enrolled-in-fourier-acc-2017 (15 May 2017) 
44. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, 
Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous 
familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016;316:743–
753.  
45. Shah P, Glueck CJ, Jetty V, Goldenberg N, Rothschild M, Riaz R, Duhon G, Wang P. 
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for 
diagnosis and treatment to a cholesterol treatment center. Lipids Health Dis 2016;15:132.  
46. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-
density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland 
Coronary Prevention Study. Circulation 2016;133:1073-1080. 
47. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, 
Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. 
Recommendations for conduct, methodological practices, and reporting of cost-effectiveness 
analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 2016;316:1093-
1103. 
48. Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, 
Bayes-Genis A, Hout BV. Cost-effectiveness of evolocumab in patients with high cardiovascular 
risk in Spain. Clin Ther 2017;39:771-786. 
49.  Descamps OS, Bruniaux M, Guilmot PF, Tonglet R, Heller FR.  Lipoprotein concentrations in 
newborns are associated with allelic variations in their mothers.  Atherosclerosis 2004;172:287-
298.  
  
{ PAGE   \* MERGEFORMAT } of 21 
 
Figure 1. Comparison of the results of FOURIER and statin trials by duration of therapy.  
 
The black line is the Cholesterol Treatment Trialists’ regression line showing average effect of 
5.1 years of treatment with a statin on the risk of major vascular events. It is calculated as a 
meta-analysis of the effect of statin therapy per mmol/L reduction in LDL-C during each year of 
treatment (column 2 of the Table).  The average effect of treatment with a statin on the risk of 
major vascular events for a given duration of therapy is calculated by meta-analysing the effect 
of statin therapy during each year of treatment up to and including the duration of interest (as 
shown in column 4 of the Table).  The figure shows that the point estimate from FOURIER (at a 
median of 2.2 years) is superimposable on the CTT regression line corresponding to the effect 
of 2 years of treatment with a statin.  The CARE, WOSCOPS, HPS and 4S trials had a median 
duration of therapy of 5 years (and are shown in black), while the PROVE-IT and FOURIER trials 
had a median duration of therapy of approximately 2 years (and are shown in blue).  
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Year of 
treatment 
HR (95% CI) per mmol/L 
reduction in LDL-C during each 
year of treatment in CTT 
Cumulative 
duration of 
Treatment (years) 
HR (95%) per mmol/L reduction in 
LDL-C for cumulative duration of 
statin treatment in CTT 
0-1 0.88 (0.84-0.93) 1 0.88 (0.84-0.93) 
1-2 0.77 (0.73-0.82) 2 0.83 (0.80-0.86) 
2-3 0.73 (0.69-0.78) 3 0.80 (0.77-0.83) 
3-4 0.72 (0.68-0.77) 4 0.78 (0.76-0.81) 
4-5 0.77 (0.72-0.83) 5 0.78 (0.76-0.80) 
> 5 0.76 (0.69-0.85) 6 0.78 (0.76-0.80) 
Overall 0.78 (0.76-0.80) Mean 5.1 0.78 (0.76-0.80) 
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Figure 2. Clinical decision algorithm for the use of a PCSK9 inhibitor in patients with ASCVD and 
with substantial residual LDL-C burden despite maximally tolerated statin ± ezetimibe therapy 
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Figure 3. Clinical decision algorithm for the use of a PCSK9 inhibitor in FH patients without 
clinically diagnosed ASCVD and with substantial residual LDL-C burden despite maximally 
tolerated statin + ezetimibe therapy 
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Figure 4. Monitoring response to statin, ezetimibe and a PCSK9 inhibitor in patients with ASCVD 
or FH patients without clinically diagnosed ASCVD 
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Box 1. Key reasons for termination of bococizumab 
The development of bococizumab was discontinued by Pfizer in late 2016.*  The key reasons 
for this were a high level of immunogenicity and wide variability in the LDL-C lowering 
response.  
 
• Immunogenicity: In statin-treated patients, PCSK9 inhibition with bococizumab reduced 
LDL-C levels by 55-60% in the short-term, but this effect was attenuated over time in 10-
15% of patients due to the development of anti-drug antibodies. It is important to note 
that this effect was specific to bococizumab, a partially humanized monoclonal antibody, 
which is characterized by substitution of rodent DNA sequences for <5% of human DNA 
sequences. It is thought that this substitution may have directly affected the LDL binding 
region of bococizumab. This effect has not been reported for either evolocumab or 
alirocumab, which are fully human monoclonal antibodies.  
 
This immunogenicity may also explain the higher rate of injection site reactions (~10%) 
observed with bococizumab compared with either alirocumab or evolocumab (<5%).  
 
• Variability in LDL-C lowering response:  Irrespective of the presence or absence of anti-
drug antibodies, there was wide individual variability in the LDL-C lowering response with 
bococizumab; about 1 in 10 showed no reduction in LDL-C levels.  
* Press release Tuesday, 1st November 2016. Pfizer Discontinues Global Development of 
Bococizumab, Its Investigational PCSK9 Inhibitor.  
http://www.pfizer.com/news/press-release/press-release-
detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_
inhibitor 
 
Box 2. Role of imaging in identifying patients with complex, extensive ASCVD  
 
ASCVD is often asymptomatic, but yet is associated with CV events and mortality. Thus a patient who 
presents with MI, is likely to have some element of AS elsewhere eg carotid vessels, peripheral 
vessels. Outcome is poorer in those with multisystem ASCVD, and treatment should be aggressive in 
these cases. Detection of multisystem disease can be enhanced by simple non-invasive tests 
• Ankle Brachial Pressure Index measurement in PAD. A ratio of <0.9 is diagnostic of PAD 
• Colour Doppler scanning of carotid vessels allows degree of stenosis (if any), plaque type and 
blood flow to be assessed. 
• More complex Magnetic Resonance Angiography (MRA) imaging confirms ASCVD in these 2 
regions and also can be used to detect renal artery stenosis, again lesions associated with a 
poorer prognosis in terms of CV Events 
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Box 3. Gaps in knowledge 
• Variability in LDL-C lowering response to alirocumab and evolocumab 
• Dedicated trials in patients with recent (<1 month) cardiovascular events  
• Impact of PCSK9 inhibition in patients with chronic kidney disease (not requiring dialysis)  
• Long-term efficacy and safety of PCSK9 inhibitors in clinical use 
• Long-term safety of very low LDL-C levels 
• Long-term impact of PCSK9 inhibition on disability and cardiovascular mortality 
• Impact of sustained and marked LDL-C lowering to very low levels on plaque composition 
and stability 
• Long-term impact of reduction in elevated lipoprotein(a) with PCSK9 inhibition 
• Cost-effectiveness of PCSK9 inhibition added to maximally tolerated statin ± ezetimibe 
therapy 
 
